Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

OpenAI reaches a research automation milestone as AI agents take on complex tasks and accelerate experiments across its research teams.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Alphabet demonstrates prodigious Google Cloud growth, with quarterly revenue surging from $20B to $25B in just one quarter.

Plenty of comparisons have been made in recent years between fast-developing artificial intelligence systems and HAL, the rogue computer in Stanley Kubrick’s “2001: A Space Odyssey” that operated by ...

AbCellera Biologics (ABCL) stock and other AI-driven healthcare companies rise as the FDA plans to create a new deputy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...